Elsevier

European Urology

Volume 71, Issue 6, June 2017, Pages 883-885
European Urology

Platinum Priority – Editorial
Referring to the article published on pp. 874–882 of this issue
Practical Polling for Prostate Cancer: AR-V7–based Treatment Selection

https://doi.org/10.1016/j.eururo.2016.12.028Get rights and content

Section snippets

Conflicts of interest

The authors have nothing to disclose.

References (16)

There are more references available in the full text version of this article.

Cited by (3)

  • Liquid biopsy approach in the management of prostate cancer

    2018, Translational Research
    Citation Excerpt :

    This study provides evidence that men with non-nuclear AR-V7 still exhibit some PSA responses to ARSis.39 The predictive capacity of an isolated CTC vs AR-V7 mRNA transcripts in a pooled sample are under evaluation in 2 independent validation studies for which reports are expected in near future.41 The role of AR-V7 as a treatment response biomarker is not only limited to ARSis.

  • Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists’ perspective

    2017, Urological Science
    Citation Excerpt :

    Scher et al. have shown that approximately 20% of resistances can be identified using this method making it a promising means of non-invasive molecular profiling for mCRPC. However, it has not yet demonstrated an ability to surpass or complement the need for nuclear-specific protein localization.65,66 The treatment landscape continues to change.

View full text